BEVACIZUMAB USE IN METASTATIC COLORECTAL CANCER IN THE FACILITIES OF DAY HOSPITAL OF REGIONAL ОNCOLOGY DISPENSARY
https://doi.org/10.17650/2220-3478-2014-0-3-35-38
Abstract
Purpose. To conduct retrospective analysis of first line therapy with bevacizumab received by patients treated in Perm Regional Oncology Dispensary.
Methods. Analysis of treatment results of 28 patients who received first line metastatic colorectal cancer (mCRC) treatment including bevacizumab in Perm Regional Oncology Dispensary. Patients received bevacizumab 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with FOLFOX, XELOX or capecitabin monotherapy in first line treatment until disease progression. Patients continued bevacizumab with change of chemotherapy regimen after first disease progression if it was possible due to performance status.
Results. Disease control was reached in 21 (75 %) cases. Complete remission was detected in 3 (10.7 %) of patients, partial remission in 9 (32.15 %), disease stabilization in 9 (32.15 %) and disease progression in 7 (25.0 % ) of patients. Median time to progression was 12 months (from 4 to 36 months). R0 liver metastases resection was performed in 9 (35.7 %) patients after treatment. Median Overall Survival was 25 months.
Conclusions. The results of retrospective analysis are in line with the data of International Clinical Trials of bevacizumab in the mCRC therapy. Continuous bevacizumab treatment from first line with the following maintenance until disease progression and further continuation in second line treatment with the chemotherapy regimen change until progression made possible to increase the efficacy and survival of patients. Bevacizumab demonstrated good tolerability and did not increase toxicity of chemotherapy.
About the Authors
T. A. MalyshevaRussian Federation
O. A. Orlov
Russian Federation
References
1. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013.
2. Saltz L.B., Clarke S., Dнaz-Rubio E. et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013–9.
3. Dнaz-Rubio Е., Gуmez-Espaсa A., Massutн B. et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2011;17(1):15–25.
4. Hochster H.S., Grothey A., Hart L. et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 2014;25(6):1172–8.
5. Koopman M., Simkens L., May A.M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3504).
6. Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 2013;14(1):29–37.
7. Grothey A., Sugrue M.M., Purdie D.M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326–34.
8. Cohn A.L., Bekaii-Saab T., Bendell J.C. et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010;28:15s (suppl; abstr 3596).
9. Поддубная И.В., Бичурина С.А., Бобровская Е.В. Использование Авастина в клинической практике у больных мета-статическим колоректальным раком. Второй промежуточный анализ наблюдательной программы АЯКС. Современная онкология 2014;1(16).
Email this article 